{
    "Clinical Trial ID": "NCT01783444",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Everolimus 10 mg + Exemestane 25 mg",
        "  Everolimus (10 mg daily) with Exemestane (25 mg daily) (control arm).",
        "INTERVENTION 2: ",
        "  Everolimus 10 mg",
        "  Everolimus (10 mg daily) (investigational arm)."
    ],
    "Eligibility": [
        "Key Inclusion Criteria:",
        "  - Women with locally advanced, recurrent, or metastatic breast cancer along with confirmation of estrogen-receptor positive (ER+). Measurable disease defined as at least one lesion  10 mm by CT or MRI that can be accurately measured in at least one dimension (CT scan slice thickness  5 mm) OR  Bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease as defined above.",
        "  Key Exclusion Criteria:",
        "  - Patients who received more than one chemotherapy line. Patients with only non-measurable lesions other than lytic or mixed (lytic and blastic) bone metastasis.Previous treatment with exemestane, mTOR inhibitors, PI3K inhibitors or AKT inhibitors."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Everolimus Alone",
        "  Progression Free Survival (PFS) is defined as the time from date of randomization to the date of first radiologically documented progression or death due to any cause. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. PFS was compared between the everolimus + exemestane combination therapy with the everolimus monotherapy.",
        "  Time frame: Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to 39 months",
        "Results 1: ",
        "  Arm/Group Title: Everolimus 10 mg + Exemestane 25 mg",
        "  Arm/Group Description: Everolimus (10 mg daily) with Exemestane (25 mg daily) (control arm).",
        "  Overall Number of Participants Analyzed: 104",
        "  Median (90% Confidence Interval)",
        "  Unit of Measure: Months  8.41        (6.60 to 9.72)",
        "Results 2: ",
        "  Arm/Group Title: Everolimus 10 mg",
        "  Arm/Group Description: Everolimus (10 mg daily) (investigational arm).",
        "  Overall Number of Participants Analyzed: 103",
        "  Median (90% Confidence Interval)",
        "  Unit of Measure: Months  6.77        (5.52 to 7.20)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 37/104 (35.58%)",
        "  Anaemia 1/104 (0.96%)",
        "  Febrile neutropenia 0/104 (0.00%)",
        "  Leukopenia 0/104 (0.00%)",
        "  Neutropenia 0/104 (0.00%)",
        "  Pancytopenia 0/104 (0.00%)",
        "  Thrombocytopenia 0/104 (0.00%)",
        "  Atrial fibrillation 1/104 (0.96%)",
        "  Cardiac arrest 1/104 (0.96%)",
        "  Cardiac failure 1/104 (0.96%)",
        "  Cardiac failure acute 1/104 (0.96%)",
        "  Cardiac failure congestive 0/104 (0.00%)",
        "Adverse Events 2:",
        "  Total: 30/103 (29.13%)",
        "  Anaemia 3/103 (2.91%)",
        "  Febrile neutropenia 0/103 (0.00%)",
        "  Leukopenia 0/103 (0.00%)",
        "  Neutropenia 0/103 (0.00%)",
        "  Pancytopenia 0/103 (0.00%)",
        "  Thrombocytopenia 0/103 (0.00%)",
        "  Atrial fibrillation 0/103 (0.00%)",
        "  Cardiac arrest 0/103 (0.00%)",
        "  Cardiac failure 0/103 (0.00%)",
        "  Cardiac failure acute 0/103 (0.00%)",
        "  Cardiac failure congestive 1/103 (0.97%)"
    ]
}